Hematopoiesis News Volume 7.16 | Apr 26 2016

MiR-22 Has a Potent Anti-Tumor Role with Therapeutic Potential in Acute Myeloid Leukemia
Researchers showed that miR-22 is an essential anti-tumor gatekeeper in de novo acute myeloid leukemia where it is significantly downregulated. Forced expression of miR-22 significantly suppressed leukemic cell viability and growth in vitro, and substantially inhibited leukemia development and maintenance in vivo. [Nat Commun] Full Article | Press Release

MEK and PI3K-AKT Inhibitors Synergistically Block Activated IL7-Receptor Signaling in T-Cell Acute Lymphoblastic Leukemia
Researchers showed that inhibiting both the MEK and PI3K-AKT pathways synergistically prevents the proliferation of BaF3 cells expressing mutant IL7Ra, JAK, and RAS. [Leukemia] Full Article

Long-Term In Vitro Maintenance of Clonal Abundance and Leukemia-Initiating Potential in Acute Lymphoblastic Leukemia
Investigators showed that Nestin-positive human mesenchymal stem cells support expansion of a range of biologically and clinically distinct patient-derived acute lymphoblastic leukemia samples. [Leukemia] Full Article

Erythroleukemia Cells Acquire an Alternative Mitophagy Capability
Using CRISPR/Cas9 deletion of the canonical autophagy-essential gene Atg7, scientists found that erythroleukemia K562 cells are armed with two sets of autophagic machinery. [Sci Rep] Full Article

Transcriptional, Epigenetic and Retroviral Signatures Identify Regulatory Regions Involved in Hematopoietic Lineage Commitment
Investigators defined the transcriptional and epigenetic profile of human hematopoietic stem/progenitor cells and early myeloid and erythroid progenitors by a combination of cap analysis of gene expression, ChIP-seq and Moloney leukemia virus integration site mapping. [Sci Rep] Full Article

Endothelial Cell-Selective Adhesion Molecule Expression in Hematopoietic Stem/Progenitor Cells Is Essential for Erythropoiesis Recovery after Bone Marrow Injury
To determine the physiological importance of endothelial cell-selective adhesion molecule (ESAM) in erythroid recovery, ESAM-knockout (KO) mice were treated with the anti-cancer drug, 5-fluorouracil (5-FU). ESAM-KO mice experienced severe and prolonged anemia after 5-FU treatment compared to wild-type mice. [PLoS One] Full Article

CLINICAL RESEARCH

Incidence and Risk Factors of Poor Graft Function after Allogeneic Stem Cell Transplantation for Myelofibrosis
The authors retrospectively studied a cohort of 100 patients with primary myelofibrosis (MF) or post-ET/PV MF who received a reduced-intensity hematopoieteic stem cell transplantation. [Bone Marrow Transplant] Abstract

Autologous Transplant Remains the Preferred Therapy for Relapsed APL in CR2
Data on patients in CR2 were collected from two large transplant registries. The outcome of patients in CR2 who received only arsenic trioxide (ATO)-based therapy as reinduction was retrospectively compared with those who got an auto-hematopoietic cell transplantation, with or without ATO. [Bone Marrow Transplant] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.

AbbVie, University of Chicago Collaborate to Advance Cancer Research
The University of Chicago and AbbVie have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations. [The University of Chicago] Press Release

AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates
AbbVie and CytomX Therapeutics, Inc. announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71 [AbbVie] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Scientist – Hematology (STEMCELL Technologies Inc.)

Full Member Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Epigenetic Mechanisms of Myeloproliferative Neoplasms and Myeloid Leukemia (State University of New York)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Engineering Project Lead (Cytonome)

Postdoctoral Fellow – Hematopoietic and Leukemic Stem Cells (The Francis Crick Institute)

Postdoctoral Scientist – Hematological Malignancies (Max Delbruck Center for Molecular Medicine in the Helmholtz Association)

Postdoctoral Fellow – Molecular and Cellular Basis of Hematopoiesis (University of Cincinnati)

Postdoctoral Research Associate – Blood Stem Cell Microenvironment (University of Illinois)

Associate Scientist – Hematopoietic Stem Cell Biology (Editas Medicine)

Research Associate – Hematopoietic Stem Cell Biology (Editas Medicine)

Postdoctoral Fellow Positions – Leukemogenesis (The University of Alabama)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.